INTRODUCTION {#sec1-1}
============

Human metapneumovirus (hMPV) was discovered in 2001 in the Netherlands from a nasopharyngeal aspirate of young children with acute respiratory tract infection \[Van den Hoogen et al., [2001](#bib46){ref-type="ref"}\]. Since then, hMPV has been identified frequently in respiratory tract infections worldwide \[Kahn, [2006](#bib28){ref-type="ref"}\], and lately recognized as a major cause of lower respiratory tract infections in infants, elderly, and immunocompromised patients \[Bao et al., [2008](#bib6){ref-type="ref"}\]. Around 12% of all respiratory tract infections in children are caused by hMPV \[Kahn, [2006](#bib28){ref-type="ref"}\], and almost all children are infected by the age of 5 \[Van den Hoogen et al., [2001](#bib46){ref-type="ref"}\]. Human metapneumovirus also accounts for 10% of all hospitalizations of elderly patients with respiratory tract infections \[Falsey et al., [2003](#bib18){ref-type="ref"}\], and is a significant pathogen in immunocompromised patients \[Muir and Pillay, [1998](#bib38){ref-type="ref"}; Williams et al., [2005](#bib51){ref-type="ref"}\].

The clinical symptoms associated with hMPV infections are very similar to those symptoms observed in respiratory syncytial virus (RSV) infection. Human metapneumovirus can cause both upper and lower respiratory tract infections, such as bronchitis, bronchiolitis, and pneumonia \[Boivin et al., [2002](#bib9){ref-type="ref"}\], as well as asthma exacerbation \[Kahn, [2003](#bib27){ref-type="ref"}\]. Symptoms such as fever, cough, tachypnea, wheezing, and hypoxia are frequently observed in infected children, and in children with a clinical syndrome consistent with bronchiolitis, hyperinflation, as well as focal infiltrates and peribronchial cuffing \[Williams et al., [2004](#bib50){ref-type="ref"}\]. Some reports have shown that hMPV infection is associated with encephalitis, and there is at least one example where hMPV was detected in a patient who died of complications associated with encephalitis \[Schildgen et al., [2005](#bib43){ref-type="ref"}\]. In addition, some studies have reported a hospital‐acquired hMPV infection in infants, children, and elderly patients in long‐term care facilities \[Chano et al., [2005](#bib14){ref-type="ref"}; Honda et al., [2006](#bib25){ref-type="ref"}; Boivin et al., [2007](#bib11){ref-type="ref"}; Kim et al., [2009](#bib31){ref-type="ref"}\].

Genetic analysis revealed a relatively high degree of sequence variability between different hMPV isolates, and two major subgroups A and B were identified. Subsequent genetic analysis led to a further subdivision of the hMPV A and B subgroups into the subtypes 1A, 2A, 1B, and 2B \[Biacchesi et al., [2003](#bib8){ref-type="ref"}\]. Moreover, subgroup A2 was further subdivided into two minor subgroups A2a and A2b \[Huck et al., [2006](#bib26){ref-type="ref"}\]. Although viral respiratory tract infections are very common in Kuwait and responsible of acute respiratory diseases and pneumonia \[Hijazi et al., [1996](#bib23){ref-type="ref"}, [1997](#bib24){ref-type="ref"}\], the prevalence of hMPV infection is not yet documented in Kuwait. The aims of this study were therefore to determine the prevalence of hMPV infection in Kuwait in patients with respiratory tract infections with respect to the other respiratory viruses, to identify the type of circulating hMPV, and to determine the seasonal distribution of hMPV infection.

MATERIALS AND METHODS {#sec1-2}
=====================

Specimen Collection {#sec2-1}
-------------------

All respiratory samples were collected during January--December, 2009 from different hospitals in Kuwait; 236 (51%) were from the Mubarak Al‐Kabir Hospital, 136 (30%) from the Al‐Sabah Hospital, 31 (7%) from the Farwanya Hospital, 23 (5%) from the Amiri Hospital, 11 (2.5%) from the Abdul‐Aziz Al‐Rashed Allergy Center, 9 (2%) from the Organ Transplant Center, 4 (1%) from the Adan Hospital, 4 (1%) from the Ibn‐Sina Hospital, 4 (1%) from the Jahra Hospital, 1 (0.3%) from the Infectious Diseases Hospital, and 1 (0.3%) from the Kuwait Cancer Center. Since the year of 2009 had witnessed the H1N1 pandemic, respiratory samples that were H1N1 positive starting from August to December have been excluded. The 460 respiratory samples were obtained from 388 patients, 210 (54%) were males and 178 (46%) were females, with either upper (n = 94, 24%) or lower (n = 294, 76%) respiratory tract infections of all age groups, from 0 day up to 80 years, and from different nationalities. The respiratory samples included bronchoalveolar lavage, endotracheal tube secretions, tracheal aspirate, throat swab, nasopharyngeal aspirate, nasopharyngeal swab, nasal swab, nasal and throat swabs, and pleural fluid. All respiratory samples were collected after obtaining written informed consent from patients. The ethical permission on this research study was granted by the Ethical Decision Committee of the Research Administration, Faculty of Medicine, Kuwait University.

Viral RNA Extraction {#sec2-2}
--------------------

The hMPV RNA extraction was done using the automated nucleic acid extraction method, MagNA Pure LC 2.0 (Roche Diagnostics Ltd, Rotkreuz, Switzerland). All 460 respiratory samples were extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer\'s instruction.

Real‐Time RT‐PCR for Detection of hMPV RNA {#sec2-3}
------------------------------------------

The hMPV RNA was detected using a commercial real‐time PCR detection assay that amplifies the hMPV nucleoprotein gene (PrimerDesign, PrimerDesign^TM^ Ltd, Southampton, Hants, UK), in combination with the AgPath‐ID^TM^ one‐step RT‐PCR mix reagent (Ambion, Applied Biosystems, Austin, TX). RT‐PCR master mix was prepared on ice by adding 12.5 µl of 2× RT‐PCR buffer, 1.5 µl of the pathogen specific primer/probe mix, 1 µl of 25× RT‐PCR enzyme mix, 4 µl nuclease‐free water, and 6 µl of the extracted RNA sample. The Applied Biosystem 7500 Fast Real‐Time PCR System (Applied Biosystems, Foster City, CA) was used for hMPV detection according to the following cycling: 45°C for 10 min, 95°C for 10 min, 50 cycles of 95°C for 15 sec, and 60°C for 60 sec.

Detection of Other Respiratory Viruses by PCR {#sec2-4}
---------------------------------------------

In addition to the hMPV detection, all samples were also tested for other respiratory viruses as described elsewhere \[Khadadah et al., [2010](#bib30){ref-type="ref"}\]. Briefly, a single PCR was used to detect adenovirus and parainfluenza virus‐2 (PIV‐2); duplex PCR was carried out to detect influenza A and B viruses; triplex PCR was carried out to detect respiratory syncytial virus (RSV), parainfluenza viruses (PIV) ‐1 and ‐3, and another triplex PCR was performed to detect human rhinovirus, human coronaviruses‐229E and ‐OC43 \[Khadadah et al., [2010](#bib30){ref-type="ref"}\].

Genotyping of Detected hMPV RNA {#sec2-5}
-------------------------------

A set of degenerate primers was selected on the basis of sequences published by Mackay et al. \[[2003](#bib33){ref-type="ref"}\] (forward primer hMPVF; 5′‐AAYMGWGTRYTAAGTGATGCRCTC‐3′, nucleotide position 601--624, and reverse primer hMPVR; 5′‐CAKTGTYTGRCCRGCHCCRTAA‐3′, nucleotide position 792--813) to amplify the N gene (hMPV isolate 00‐1, GenBank accession number under AF371337). The RT‐PCR was performed using the Qiagen One‐Step RT‐PCR Kit (Qiagen, Hilden, Germany). The reaction mixture was exposed to a 30 min, 45°C reverse transcription incubation, and then 40 cycles of 94°C for 20 sec, 50°C for 20 sec, and 68°C for 20 sec, with a final 68°C extension for 7 min using the GeneAmp® PCR System 9700 (Applied Biosystems). The RT‐PCR amplification reaction resulted in a 213‐bp PCR product when separated by 2% agarose gel electrophoresis and visualized by ethidium bromide staining.

The PCR fragments were purified with QIAquick PCR purification columns as described by the manufacturer (Qiagen, Suite, Valencia), and both strands were directly sequenced with both hMPVF and hMPVR primers using the ABI PRISM® BigDye® Terminator Cycle Sequencing v3.1 Ready Reaction kit (Applied Biosystems). Labeled DNA fragments were separated and detected using ABI genetic analyzer 3130 (Applied Biosystems). The obtained sequences were then analyzed for genotype identification using Basic Local Alignment Search Tool (BLAST) alignment from GenBank (<http://www.ncbi.nlm.nih.gov/Blast.cgi>) and compared to sequences available from the GenBank database (GenBank accession numbers were as follows: Subgroup A1, AF371337; subgroup A2a, NC_004148, FJ168779, and AB503857; subgroup A2b, DQ843659, and GQ153651; subgroup B1, AY525843; and subgroup B2, DQ843658, AY297748, and FJ168778).

Statistical Analysis {#sec2-6}
--------------------

The difference in the hMPV viral load between different groups of patients was assessed using Mann--Whitney and Kruskal--Wallis tests. The significance of the difference in categorical variables among various groups was tested using the χ^2^‐test and Fisher exact test, as appropriate. The statistical analysis was performed using SPSS v17.0 software (SPSS Inc., Chicago, IL).

RESULTS {#sec1-3}
=======

The clinical data of the study population is shown in Table [I](#tbl1){ref-type="table"}. All H1N1‐negative respiratory samples were screened for hMPV and other respiratory viruses. Table [II](#tbl2){ref-type="table"} shows that rhinovirus was the most detected virus in clinical respiratory specimens of patients with respiratory symptoms (6.3%), followed by hMPV (5%), respiratory syncytial virus (3%), and adenovirus (2.8%). Coronavirus‐OC43 and parainfluenza virus type 2 were not detected. The prevalence of hMPV infection in patients with respiratory tract infections was 5.4%. Human metapneumovirus was also found in the presence of rhinovirus in three patients (1%), and adenovirus in one patient (0.3%), with a co‐infection rate of 1%.

###### 

Clinical Data of the Study Population

  Respiratory symptoms                       Patients, n (%)
  ------------------------------------------ -----------------
  Lower respiratory tract infection          
   Pneumonia                                 137 (35%)
   Bronchopneumonia                          36 (9%)
   Bronchiolitis                             38 (10%)
   Acute exacerbations of bronchial asthma   16 (4%)
   COPD                                      6 (1.6%)
   Pulmonary edema                           1 (0.3%)
   Pulmonary hypertension                    1 (0.3%)
   Respiratory distress                      1 (0.3%)
   Respiratory failure                       7 (2%)
   Wheezy chest                              2 (0.5%)
   Unspecified LRTI symptoms                 49 (13%)
   Total                                     294 (76%)
  Upper respiratory tract infection          94 (24%)
  Total                                      388 (100%)

COPD, chronic obstructive pulmonary disease.

Upper respiratory tract infections include: Cough, Rhinitis, Fever, Tonsillitis, and Flu‐like Illnesses.
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###### 

Nucleic Acid Detection of Respiratory Viruses in Clinical Specimens From Patients With Respiratory Symptoms

  Respiratory viruses     Patients, n (%)
  ----------------------- -----------------
  hMPV                    21 (5.4%)
  RSV                     13 (4%)
  Adenoviruses            10 (3%)
  Influenza‐A             5 (1.3%)
  Influenza‐B             1 (0.3%)
  Rhinoviruses            29 (7.5%)
  PIV‐1                   10 (3%)
  PIV‐2                   0
  PIV‐3                   6 (1.5%)
  Corona‐229E             1 (0.3%)
  Corona‐OC43             0
  hMPV/Rhinovirus         3 (1%)
  hMPV/Adenovirus         1 (0.3%)
  Rhinovirus/RSV          2 (0.5%)
  Rhinovirus/Adenovirus   1 (0.3%)
  Rhinovirus/PIV‐1        1 (0.3%)
  Rhinovirus/PIV‐3        2 (0.5%)
  PIV‐1/PIV‐3             4 (1%)
  Total                   110 (28%)

hMPV, human metapneumovirus; RSV, respiratory Syncytial virus; PIV, parainfluenza virus.
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The hMPV‐positive patients were segregated according to their sex, age, and intensive care unit/ward admission (Table [III](#tbl3){ref-type="table"}). The overall proportion of hMPV infection in females was 7% (n = 13) and that in males was 4% (n = 8) (*P* = 0.13). Most of the hMPV‐positive patients (76%) were infants having less than 2 years, while 24% of them were patients having 59 years and above, and the overall prevalence of hMPV infection in infants and elderly was 11 and 8%, respectively. The hMPV infection was not detected among children aged more than 2 years and adults aged less than 59 years. Most of the hMPV‐positive patients (90%) were admitted to the intensive care unit; the overall proportion of hMPV infection in patients admitted to intensive care unit was 8%. The hMPV was only detected in the following types of respiratory samples: Endotracheal tube secretions (30%), tracheal aspirate (30%), nasopharyngeal aspirate (30%), and nasopharyngeal swab (10%). The difference in the hMPV RNA load among different types of respiratory samples was not significant.

###### 

Characteristics of hMPV‐Positive Patients

                         Patient, n (%)
  ---------------------- ----------------
  Sex                    
   Male                  8 (4%)
   Female                13 (7%)
   Total                 21 (5.4%)
  Age                    
   \<2 years             16 (11%)
   \>59 years            5 (8%)
  Hospital admission     
   Ward                  2 (1%)
   Intensive Care Unit   19 (8%)
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All hMPV‐positive patients had lower respiratory tract infections with high detectable RNA load. All elderly patients (n = 5) had pneumonia, while 50% (n = 8) of infants less than 2 years had bronchopneumonia, 25% (n = 4) had pneumonia, and 13% (n = 2) had acute exacerbation of bronchial asthma. The median hMPV RNA load for each group of patients according to their clinical data was as the following: 1.76 × 10^6^ copies/ml for patients with pneumonia, 4.08 × 10^7^ copies/ml for patients with bronchopneumonia, and 2.31 × 10^8^ copies/ml for patients presented with acute exacerbation of bronchial asthma. In addition, one patient with bronchiolitis had hMPV RNA load of 7.68 × 10^7^ copies/ml, and one with respiratory distress had 4.48 × 10^6^ copies/ml. The difference in the viral load between each group of patients with lower respiratory tract infection was not significant (*P* = 0.55). The median hMPV RNA load in infants aged 2 years and below (9.48 × 10^6^ copies/ml) was not statistically different from that in old patients aged 59 years and above (1.31 × 10^7^ copies/ml) (*P* = 0.89). The genotype of hMPV RNA detected was identified by direct sequencing. Eleven hMPV RT‐PCR products could be sequenced showing high similarity with hMPV sequences available in the GenBank database. Two hMPV genotypes were detected, A subgroup 2b and B subgroup 2; although genotype B2 was more prevalent than A2b (Table [IV](#tbl4){ref-type="table"}). The hMPV infection was detected during winter and spring seasons (Fig. [1](#fig1){ref-type="fig"}), with high incidence rate in spring, and with very low incidence during summer (*P* = 0.005).

###### 

Genotypes of Detected hMPV in Patients With Respiratory Tract Infections

  Patient   Age         Sex      Clinical Diagnosis                       hMPV RNA Load copies/ml   hMPV Genotype (Homology %)[a](#fn1){ref-type="fn"}
  --------- ----------- -------- ---------------------------------------- ------------------------- ----------------------------------------------------
  A         2 months    Female   Bronchiolitis                            7.68 × 10^7^              B2 (99%)
  B         5 months    Female   Bronchopneumonia                         6.78 × 10^8^              A2b (97%)
  C         5 months    Female   Respiratory Distress                     4.48 × 10^6^              B2 (97%)
  D         6 months    Male     Bronchopneumonia                         8.97 × 10^6^              B2 (97%)
  E         9 months    Female   Bronchopneumonia                         1.61 × 10^6^              B2 (97%)
  F         10 months   Female   Bronchopneumonia                         1.44 × 10^9^              B2 (92%)
  G         1 year      Female   Pneumonia                                5.73 × 10^8^              B2 (99%)
  H         2 years     Female   Acute Exacerbation of Bronchial Asthma   4.62 × 10^8^              B2 (97%)
  I         59 years    Male     Pneumonia                                9.39 × 10^5^              A2b (95%)
  J         67 years    Male     Pneumonia                                1.47 × 10^10^             B2 (99%)
  K         70 years    Female   Pneumonia                                4.21 × 10^9^              B2 (99%)

Homology with reference genome from GenBank database.
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![The seasonal distribution of hMPV infection in Kuwait.](JMV-83-1811-g001){#fig1}

DISSCUSSION {#sec1-4}
===========

This is the first study in Kuwait exploring the importance of hMPV infection among patients with respiratory tract infections in hospitals. Previous studies on hMPV infection have been published in the Middle East area however, most of them have focused on one age group, children less than 5 years \[Al‐Sonboli et al., [2005](#bib2){ref-type="ref"}; Regev et al., [2006](#bib42){ref-type="ref"}; Arabpour et al., [2008](#bib5){ref-type="ref"}; Kaplan et al., [2008](#bib29){ref-type="ref"}; Ali et al., [2010](#bib1){ref-type="ref"}; Moattari et al., [2010](#bib37){ref-type="ref"}\]. Not surprising, most of respiratory samples collected in this study were from infants less than 2 years, showing that the most affected age group vulnerable for respiratory infections is infants. Infants are considered to be at high risk for respiratory infections, since their immunity system is being progressively developed during their first 2 years \[File, [2000](#bib19){ref-type="ref"}\]. Respiratory infections are considered as a major cause of morbidity and mortality in developing countries \[Campbell, [1995](#bib13){ref-type="ref"}\], and this agrees with our observation that most of the respiratory samples (65%) were collected from patients admitted to the intensive care unit for acute lower respiratory tract infections.

In the current study, rhinovirus was found to be the major cause of acute respiratory infections followed by hMPV and then respiratory syncytial virus. These results are in agreement with a previous study done in Kuwait showing that respiratory syncytial virus and human rhinovirus were the major cause of severe lower respiratory tract infections in Kuwait \[Khadadah et al., [2010](#bib30){ref-type="ref"}\]. In addition, the best respiratory samples for hMPV detection were endotracheal tube secretions, tracheal aspirate, nasopharyngeal aspirate followed by nasopharyngeal swab, whereas hMPV RNA was not detected in throat swab, nasal swab, bronchoalveolar lavage and pleural fluid. This support earlier studies which recommended nasopharyngeal aspirate and swabs specimens for hMPV detection \[Van den Hoogen et al., [2001](#bib46){ref-type="ref"}, [2004a](#bib47){ref-type="ref"}\]. The prevalence of hMPV infection among the study population was 5.4%. Previous studies have reported that it accounts for at least 5 to 7% of the respiratory tract infections in hospitalized children, and at least 3% in the general community of patients who visit a general practitioner for respiratory tract infections \[Van den Hoogen et al., [2004b](#bib48){ref-type="ref"}\].

Most of the hMPV‐positive patients were of age 2 years and less (76%), and of age 59 years and above (24%), and these results parallel most if not all studies that have shown that hMPV is a common disease in children and can cause severe infections in the elderly \[Falsey et al., [2003](#bib18){ref-type="ref"}; Wolf et al., [2003](#bib52){ref-type="ref"}; Principi et al., [2006](#bib41){ref-type="ref"}; Hermos et al., [2010](#bib22){ref-type="ref"}\]. In Qatar the hMPV virus was the most commonly detected virus, accounting for 74% of all respiratory infections among pediatric patients aged 1 month to 5 years, and this result is very similar to the current study finding that most of hMPV‐positive patients were of age 2 years and less than 76% \[Al‐Thani et al., [2010](#bib4){ref-type="ref"}\]. Our results highlight the importance to introduce a screening test for hMPV infection in routine diagnosis, and to have appropriate medical management for hMPV‐positive cases as other studies have recommended previously \[Deffrasnes et al., [2007](#bib16){ref-type="ref"}\]. Moreover, the clinical data of hMPV‐positive patients have shown that all elderly people presented with pneumonia mainly, while infants presented with a variety of clinical syndromes such as bronchopneumonia, pneumonia, acute exacerbation of bronchial asthma and bronchiolitis, a finding which has also been observed in previous studies \[Boivin et al., [2002](#bib9){ref-type="ref"}; Williams et al., [2004](#bib50){ref-type="ref"}\]. In this context, a study conducted on 10 elderly patients with underlying illness, has shown that four patients had developed pneumonitis and two have died due to hMPV infection \[Boivin et al., [2002](#bib9){ref-type="ref"}\].

Of the 23 hMPV‐positive patients, three (1%) were also positive for rhinovirus and one (0.3%) was positive for adenovirus, with total co‐infection rate of 1%. Some previous reports have shown a co‐infection of hMPV/respiratory syncytial virus, which correlated with the severity of infection \[Greensill et al., [2003](#bib20){ref-type="ref"}; Semple et al., [2005](#bib44){ref-type="ref"}\]. On the other hand, other studies have shown that hMPV/respiratory syncytial virus co‐infection may normally be rare in most populations \[Mackay et al., [2006](#bib34){ref-type="ref"}\], while some publications have failed to detect this co‐infection \[Esper et al., [2003](#bib17){ref-type="ref"}; Al‐Sonboli et al., [2006](#bib3){ref-type="ref"}; Van Woensel et al., [2006](#bib49){ref-type="ref"}\]. Furthermore, some recent studies have found co‐infection of hMPV with SARS‐coronavirus and human bocavirus \[Choi et al., [2006](#bib15){ref-type="ref"}; Lee et al., [2007](#bib32){ref-type="ref"}\]. The co‐infection of hMPV/rhinovirus might be responsible for the severe symptoms presented by our patients. Indeed, one 2‐years‐old female had high hMPV RNA load (4.62 × 10^8^ copies/ml) and presented with acute exacerbation of bronchial asthma. A male infant aged 2 months had recurrent chest infection with frequent intensive care unit admission, and his hMPV viral load was high (1.76 × 10^6^ copies/ml). The last patient was a 1‐year‐old female with recurrent chest infection and frequent intensive care unit admission, and her hMPV RNA load was high (5.73 × 10^8^ copies/ml). This suggests that the presence of hMPV infection with other respiratory virus may complicate the clinical condition and prolong patient stay in the hospital, as it has been reported earlier \[Greensill et al., [2003](#bib20){ref-type="ref"}; Semple et al., [2005](#bib44){ref-type="ref"}; Xiao et al., [2010](#bib53){ref-type="ref"}\]. The high viral load of hMPV detected in our patients with lower respiratory tract infection may suggest a correlation between the severity of clinical symptoms and the virus replication rate, as described elsewhere \[Boivin et al., [2002](#bib9){ref-type="ref"}; Gerna et al., [2007](#bib21){ref-type="ref"}; Bosis et al., [2008](#bib12){ref-type="ref"}; Peng et al., [2010](#bib40){ref-type="ref"}\].

The detection of hMPV in the respiratory samples was confirmed by RT‐PCR and sequencing of the hMPV N gene as described earlier \[Mackay et al., [2003](#bib33){ref-type="ref"}\]. Sequence analysis has shown that both genotypes A and B circulate in Kuwait, with predominance of B2 subgroup. Genotype A has been reported as the predominant genotype in respiratory samples \[Bastien et al., [2003](#bib7){ref-type="ref"}; Boivin et al., [2003](#bib10){ref-type="ref"}; Maggi et al., [2003](#bib35){ref-type="ref"}; Peiris et al., [2003](#bib39){ref-type="ref"}\], but other studies have documented the presence of both genotypes A and B \[Huck et al., [2006](#bib26){ref-type="ref"}; Regev et al., [2006](#bib42){ref-type="ref"}; Matsuzaki et al., [2008](#bib36){ref-type="ref"}\].

The seasonal distribution of hMPV infection during the year 2009 indicates that hMPV infection incidence is high in winter and peaks during spring with almost no infection detected during summer. These results are not different from those of previous observations that have found high level of hMPV detection in the spring and winter months \[Sugrue et al., [2008](#bib45){ref-type="ref"}; Ali et al., [2010](#bib1){ref-type="ref"}\].
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